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Rationale: Acute-on-chronic liver failure (ACLF) is a life-threat-
ening acute deterioration of a chronic liver disease with severe
jaundice and hepatic encephalopathy. There are no cost-of-illness
studies of the treatment of ACLF available. OBJECTIVES: To
determine the average cost of the treatment of ACLF and testing
of important clinical variables for their predictive value for the
treatment costs. Methodology: Based on the sample of all ACLF-
patients treated in a large German university hospital from 1999
to 2001 detailed cost of the initial hospital stay and a three year
follow-up period were determined. Data on resource use were
collected from hospitals patient ﬁles and internal statistics as well
as by standardized interviews and questionnaires to patients and
their treating GPs. Costs were calculated from a German health
care system perspective and standardized to EUR of 2002. Addi-
tionally to age, sex, aetiology and severity of liver failure another
15 relevant clinical variables were tested in single and multiple
regression analyses. RESULTS: A total of 69 patients with ACLF
could be identiﬁed. Mean costs per patient were €21,058;
€11,259 for the initial hospital stay and €9799 for the following
3 years. Biggest inﬂuence had treatment with artiﬁcial liver
support systems. Other signiﬁcant variables in the model were
renal dialysis and aetiology of the disease. All other variables
including sex, age, severity of ACLF and several laboratory para-
meter did not have a relevant inﬂuence on the costs. CONCLU-
SION: A straight and relatively simple method to identify the
main cost drivers for ACLF-treatment is presented. The results
are absolutely plausible from a clinical point of view and stable
to variation of the model structure. The results underline the
necessity to differentiate the reimbursement systems for hepa-
torenal syndrome or additional renal failure, artiﬁcial liver
support and the aetiology of ACLF.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD) is a
chronic, potentially debilitating condition characterized by 
frequent and persistent heartburn and acid regurgitation. The
objective of this study was to evaluate the effects of GERD on
work productivity, deﬁned as productivity loss due to absen-
teeism and reduced effectiveness while working (presenteeism).
METHODS: Studies quantifying health-related work productiv-
ity loss in individuals with GERD were identiﬁed using system-
atic literature searches. Work productivity loss due to
absenteeism was expressed as number of hours lost, and as the
percentage of the total employed time. Presenteeism was
expressed as number of hours lost, and as the percentage reduced
effectiveness while at work. Overall productivity losses (absen-
teeism plus presenteeism) were valued in US dollars using the
human capital method. RESULTS: Six publications covering ﬁve
studies conducted in the USA, Canada and Sweden were eligible
for inclusion. Reported work productivity losses among individ-
uals with GERD ranged from 6% to 40%, and were primarily
due to presenteeism (6%–40%) rather than absenteeism
(<1%–6%). Work productivity impairment correlated with
symptom severity, and was greatest in patients experiencing sleep
disturbance due to GERD symptoms and lowest in GERD
patients taking prescription medication. Acid-suppressive
therapy improved productivity at work, especially in individuals
with GERD-associated sleep disturbances. The mean overall pro-
ductivity losses per employee with GERD were estimated at
$51–$396 per week, assuming a 40-hour working week and
average US wages. CONCLUSION: GERD has a substantial eco-
nomic impact, primarily by impairing employee productivity
while at work. The burden of lost productivity may be reduced
by acid-suppressive therapy, especially in employees with night-
time symptoms of GERD.
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OBJECTIVES: To compare the accuracy of two absenteeism
measures (days missed and hours missed) for inclusion in 
economic evaluations of IBS. METHODS: 135 IBS patients
recruited from ﬁve US gastroenterology practices completed the
Work Productivity and Activity Impairment questionnaire for
IBS (WPAI : IBS), which assesses absenteeism with hours missed,
and also completed questions about days and partial days
missed. Days and partial days were considered to be the equiv-
alent of 8 hours and 4 hours, respectively. RESULTS: 125
patients were employed, had complete data, and were included
in the analysis. A total of 6.4% of patients reported missing days
from work due to IBS in the prior 7 days, with an overall absen-
teeism rate of 1.8%; 28.0% of patients reported missing hours,
with an overall absenteeism rate of 4.3%. Among those report-
ing hours missed, 42.9% missed less than 3 hours, 34.3% missed
3 to 5 hours, and 22.9% missed 8 to 30 hours. When days missed
was used to measure absenteeism, 77.2% of patients missing
hours and 60.7% of time missed due to IBS were not counted;
when hours missed was reported, all patients reporting days
missed were counted. Combining partial days missed with days
missed increased the correspondence between those reporting
days and hours missed, but considerably overstated absenteeism
because partial-day absences were often less than 4 hours. Pre-
vious validation of the WPAI : IBS hours missed measure of
absenteeism relative to measures of disease severity, verbatim
responses and retrospective diaries, corroborates the inaccuracy
of the days missed measure. CONCLUSIONS: Hours missed
from work, not days missed, is a more accurate measure for cap-
turing the partial-day absences characteristic of IBS patients.
Other chronic disorders like IBS may exhibit a similar pattern of
widespread absences of short duration, and that absenteeism
may go undetected when days missed is the measure of 
absenteeism.
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OBJECTIVES: In Brazil it is estimated that there are more than
3 million patients chronically infected with HCV, making this
disease a major public health problem. HCVI leads to chronic
liver disease states such as cirrhosis and the need for transplan-
tation. There is little published data on the cost of HCVI in
Brazil. The aim of this study is to investigate medical resource
use and direct treatment costs for each state of HCV infection
from the perspective of the private medicine payers in Brazil.
METHODS: Three Delphi panels were performed, one with
hepatologists, one with intensivists and another with oncologists
in order to delineate practice patterns and to obtain resource uti-
lization for routine treatment and monitoring, adverse event
management and other clinical parameters representative 
